Claim Missing Document
Check
Articles

Found 3 Documents
Search

Indonesian Society of Respirology (ISR) Consensus Statement on Lung Cancer Screening and Early Detection in Indonesia Sita Andarini; Elisna Syahruddin; Nathaniel Aditya; Jamal Zaini; Ferry Dwi Kurniawan; Sabrina Ermayanti; Noni Novisari Soeroso; Sri Melati Munir; Andreas Infianto; Ana Rima; Ungky Agus Setyawan; Laksmi Wulandari; Haryati Haryati; Ida Ayu Jasminarti; Arif Santoso
Jurnal Respirologi Indonesia Vol 43, No 2 (2023)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v43i2.455

Abstract

Lung cancer is the leading cause of mortality for all cancer globally and in Indonesia. In Indonesia, lung cancer contributes to 12.6% of death of all cancer, making it the number one cause of cancer death, and 8.6% of all cancer incidence in 2018, behind breast, cervical, and colorectal cancer. The total cases per year are expected to almost double from 30,023 in 2018 to 54,983 cases in 2040. Smoking is among the risk factors for lung cancer, after occupational/environmental risk factors, history of lung fibrosis, and family history of cancer. There was a tendency of younger smokers in Indonesia and increased lung cancer incidence and prevalence in the younger population. The median age of lung cancer in Indonesia was younger than in any country, probably due to the younger age of smoking, early onset of carcinogens, asbestos use, and environmental. Lung cancer screening is a voluntary measure to detect lung cancer in the earliest stage, to find cancer at curable disease before symptoms appear in high-risk individuals. Lung cancer early detection is strategies to find cancer earlier after symptoms appear (cough, hemoptysis, dyspnea, chest pain). Low-dose computerized tomography of the thorax (LDCT) screening has been known to reduce lung cancer mortality compared to a chest x-ray (CXR). This Indonesian Society of Respirology consensus statement was aimed to give recommendations on lung cancer screening and early diagnosis in Indonesia.
Correlation of Smoking with Carbon Monoxide Level and Peak Expiratory Flow Rate in High School Students Banda Aceh Julie Amalliah; Sri Dianova; Ferry Dwi Kurniawan; Teuku Zulfikar; Nurrahmah Yusuf
Jurnal Respirologi Indonesia Vol 43, No 3 (2023)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v43i3.294

Abstract

Background: Indonesia has the highest number of adolescent smokers in the world. Carbon monoxide (CO) is a by-product of tobacco smoking and is inhaled into the lungs. A smokerlyzer can monitor its level. Cigarette smoke also causes inflammation that affects airflow in the airways and can be detected by measuring the peak expiratory flow rate (PEFR). This study aims to determine the relationship between smoking and CO levels and PEFR in high school students in Banda Aceh City.Methods: This quantitative study uses an analytical observational approach with a cross-sectional design. This study involved 300 students from five senior high schools in Banda Aceh. The data were analyzed using the Mann-Whitney and Spearman test with a significance value <0.05.Results: CO levels of the smoker students were higher (12.61 ± 3.342 ppm) than nonsmoker students (2.46 ± 0.569 ppm), p=0.000. The average PEFR for smoking students was lower than nonsmokers (61.11 ± 9.163%) than for non-smoking students (78.48 ± 6.804 %), p=0.000. Duration of smoking in smoking students was also strongly associated with CO levels and PEFR (r=+0.749, p=0,000, r=-0.560, p=0.000, respectively).Conclusion: There is a relationship between smoking and CO levels and PEFR in senior high school students in Banda Aceh.
Studi Perbandingan : Kualitas Hidup Pasien Kanker Paru Yang Menjalani Kemoterapi Dengan Yang Menolak Kemoterapi Ferry Dwi Kurniawan; Rinaldy; Mikhwanul Jumar
Journal of Medical Science Vol 7 No 1 (2026): Journal of Medical Science
Publisher : LITBANG RSUDZA

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55572/jms.v7i1.257

Abstract

Kanker paru merupakan salah satu penyebab kematian tertinggi akibat kanker di dunia. Selain angka kelangsungan hidup, kualitas hidup (Quality of Life/QoL) merupakan indikator penting keberhasilan terapi kanker. Penelitian ini bertujuan untuk membandingkan kualitas hidup pasien kanker paru antara kelompok yang menjalani kemoterapi dengan kelompok yang menolak kemoterapi dengan menggunakan instrumen penilaian WHOQOL-BREF.Penelitian ini merupakan penelitian observasional analitik dengan rancangan pre-test dan post-test untuk menilai perubahan kualitas hidup pasien kanker paru sebelum dan sesudah menjalani kemoterapi. Penelitian dilakukan di Ruang Rawat Inap dan Poliklinik Paru Rumah Sakit Umum Daerah dr. Zainoel Abidin Banda Aceh pada bulan Juni hingga September 2025. Populasi penelitian adalah seluruh pasien kanker paru yang menjalani pengobatan kemoterapi, dan sampel adalah pasien yang baru pertama kali menjalani kemoterapi serta memenuhi kriteria inklusi dan eksklusi. Teknik pengambilan sampel menggunakan metode consecutive sampling dengan jumlah responden sebanyak 44 orang, terdiri dari 38 pasien yang menjalani kemoterapi dan 6 pasien yang menolak kemoterapi.Kualitas hidup diukur menggunakan kuesioner WHOQOL-BREF yang mencakup empat domain, yaitu kesehatan fisik, psikologis, hubungan sosial, dan lingkungan. Hasil penelitian menunjukkan bahwa skor rata-rata kualitas hidup pasien pada keempat domain WHOQOL-BREF tidak menunjukkan perbedaan bermakna antara kelompok yang menjalani kemoterapi dan kelompok yang menolak kemoterapi. Pada domain fisik, pasien kemoterapi memiliki skor rata-rata 46,00, sedangkan pasien yang menolak kemoterapi 50,00 (p=0,461). Pada domain psikologis, rata-rata skor kelompok kemoterapi adalah 53,84 dan pasien non-kemo 54,33 (p=0,909). Pada domain hubungan sosial, pasien kemoterapi memperoleh skor rata-rata 56,47 dan pasien non-kemo 53,00 (p=0,540). Sementara itu, pada domain lingkungan, pasien kemoterapi memiliki skor rata-rata 54,37 dan pasien non-kemo 56,33 (p=0,638).Kesimpulan dari penelitian ini adalah kualitas hidup pasien kanker paru yang menjalani kemoterapi tidak berbeda bermakna dengan pasien yang menolak kemoterapi pada semua domain WHOQOL-BREF. Hal ini menunjukkan bahwa kualitas hidup pasien kanker paru kemungkinan lebih dipengaruhi oleh faktor lain seperti kondisi fisik dasar, dukungan sosial, dan lingkungan dibandingkan keputusan menjalani kemoterapi itu sendiri.